Rivaroxaban is associated with higher rates of gastrointestinal (HD) bleeding compared to other direct oral anticoagulants. This, according to a study published online October 12 in Annals of Internal Medicine.
ABOUT THE STUDY:
Arnar B. Ingason, MD, of the University of Iceland in Reykjavík, and colleagues compared BIG rates among new users of apixaban, dabigatran, and rivaroxaban from 2014 to 2019.
Data from 2,157 patients who received apixaban, 494 who received dabigatran, and 3,217 received rivaroxaban were included.
RESULTS:
The researchers found that, compared to apixaban, rivaroxaban had higher overall rates of GIB for all patients 3.2 versus 2.5 events per 100 person-years.
Risk index, 1.42; 95 percent confidence interval, 1.04 to 1.93) and higher rates of major HD (1.9 versus 1.4 events per 100 person-years; hazard ratio, 1.50; confidence interval 95 percent, 1.00 to 2.24).
Higher rates of GIB were also seen for rivaroxaban versus dabigatran, with similar point estimates. Although the confidence intervals were wider, including the possibility of a null event.
Rivaroxaban had higher rates of global HD
Compared to apixaban or dabigatran, rivaroxaban had higher rates of global HD when only patients with atrial fibrillation included (hazard ratios [intervalos de confianza del 95 por ciento], 1.40 [1,01 a 1,94] and 2.04 [1,17 a 3,55], respectively).
In both analyzes, dabigatran was associated with lower rates of superior HD compared with rivaroxaban.
“Rivaroxaban was associated with higher rates of BIG than apixaban and dabigatran,” the authors write. “This can help guide the selection of oral anticoagulants, especially for patients at high risk for HD.”
About Rivaroxaban
Rivaroxaban is the direct oral anticoagulant (DOAC) with the highest number of indications worldwide and the most prescribed in Mexico.
It currently has nine indications, protecting more patients from venous and arterial thromboembolic diseases than any other new generation oral anticoagulant.
- Prevention of Venous Thromboembolism in adults undergoing total hip replacement surgery.
- Prevention of Venous Thromboembolism in adults undergoing total knee replacement surgery.
- Prevention of Cerebral Vascular Event (CVD) and systemic embolism in adults with
- Nonvalvular Atrial Fibrillation.
- Treatment of Deep Vein Thrombosis (DVT) in adults.
- Treatment of Pulmonary Embolism (PE) in adults.
- Prevention of recurrent DVT and PE in adults.
- Prevention of atherothrombotic events (cardiovascular death, myocardial infarction or CVD) after Acute Coronary Ischemic Syndrome in adult patients.
- Coronary Artery Disease (CAD).
- Peripheral Arterial Disease (PAD).
Related Notes:
Mild COVID patients are at higher risk of heart damage
Finally! Mexico leaves the red list for risk of COVID of the Kingdom …
NATURE: Why didn’t COVID vaccines win a Nobel Prize in science this year?